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Abstract
Background: In vivo bioluminescence, fluorescence, and single-photon emission computed tomography (SPECT)
imaging provide complementary information about biological processes. However, to date these signatures are
evaluated separately on individual preclinical systems. In this paper, we introduce a fully integrated
bioluminescence-fluorescence-SPECT platform. Next to an optimization in logistics and image fusion, this integration
can help improve understanding of the optical imaging (OI) results.
Methods: An OI module was developed for a preclinical SPECT system (U-SPECT, MILabs, Utrecht, the Netherlands).
The applicability of the module for bioluminescence and fluorescence imaging was evaluated in both a phantom
and in an in vivo setting using mice implanted with a 4 T1-luc + tumor. A combination of a fluorescent dye and
radioactive moiety was used to directly relate the optical images of the module to the SPECT findings.
Bioluminescence imaging (BLI) was compared to the localization of the fluorescence signal in the tumors.
Results: Both the phantom and in vivo mouse studies showed that superficial fluorescence signals could be
imaged accurately. The SPECT and bioluminescence images could be used to place the fluorescence findings in
perspective, e.g. by showing tracer accumulation in non-target organs such as the liver and kidneys (SPECT) and
giving a semi-quantitative read-out for tumor spread (bioluminescence).
Conclusions: We developed a fully integrated multimodal platform that provides complementary registered
imaging of bioluminescent, fluorescent, and SPECT signatures in a single scanning session with a single dose of
anesthesia. In our view, integration of these modalities helps to improve data interpretation of optical findings in
relation to radionuclide images.
Keywords: Bioluminescence imaging; Fluorescence imaging; Multimodal molecular imaging; SPECT; Small animal;
Nuclear medicine
Background
Studies of human disease in animal models often pro-
vide an essential link between chemistry, fundamental
research at the molecular level, and the development/
evaluation of new diagnostic and therapeutic methods.
Molecular imaging modalities such as single-photon emis-
sion computed tomography (SPECT), positron emission
tomography (PET), bioluminescence, and fluorescence
provide a means to generate a view into the in vivo situ-
ation [1,2].
SPECT and optical technologies are complementary in
terms of resolution, speed, quantitative accuracy, and
tracer availability [3-5]. Independent of the source depth,
modern small animal SPECT systems can be used for
longitudinal and quantitative imaging studies of dynamic
processes in small structures (resolution <0.25 mm) [6].
Alternatively, optical imaging provides a rapid and low-
cost non-radioactive imaging and enables longitudinal
studies of superficial lesions. The resolution of fluores-
cence imaging also enables the (ex vivo) microscopic
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tially, a vast amount of optical tracers from molecular
cell biology can be translated to in vivo use. Alternative
to a use in combination with dedicated tracers, optical
imaging can also be used to detect transfected (tumor)
cell lines that contain e.g. luciferase or one of the fluor-
escent proteins [8], enabling the (longitudinal) monitor-
ing of disease spread and progression in animal models.
The main disadvantages for optical techniques are the
significant scatter and absorption of photons by tissue/
structures in the animal body. Fluorescence techniques
additionally suffer from tissue autofluorescence, result-
ing in an unwanted background signal. These negative
features can be partly overcome by using emissions in
the near-infrared (NIR) spectrum, but unfortunately op-
tical imaging cannot equal the detailed view and quanti-
tative accuracy that SPECT provides at larger depths.
One of the great challenges today is to place these two
modalities in perspective and to determine the added
value of optical imaging within the field of nuclear medi-
cine [9].
When multimodal tracers with both a radioactive and
fluorescent signature are used, a single tracer can pro-
vide ‘best of both worlds’. Such tracers are reported with
a peptide, monoclonal antibody, or nanoparticle basis
[10-12]. Combined radioactive and fluorescence imaging
has already provided added value in clinical surgical
guidance studies [13,14].
Next to the development of multimodal tracers that
combine two signatures, SPECT and optical modalities
can also be combined on a single device with a single
user interface. In this way, logistics, including anesthesia,
are simplified and may improve animal welfare. Because
animal positioning is no longer an issue with respect to
co-registration of the imaging results, the complemen-
tary value of the different modalities can be exploited to
its full extent; e.g. bioluminescent tumor cell localization
combined with tracer distribution imaging (fluorescence
and/or nuclear).
While other groups mainly focus on integrating
nuclear imaging with three-dimensional (3D) fluo-
rescence optical tomography (FOT) imaging [15-18]
or fluorescence-mediated tomography (FMT) [19], we
consider optical imaging, both bioluminescence and
fluorescence, as intrinsically superficial technology, cur-
rently most suitable for planar imaging. Today, planar
imaging is applied in the far majority of optical imaging
studies in preclinical research since optical tomography
is still highly challenging due to the ill-posed nature of
optical data caused by strong light absorption and dif-
fusion [20]. Therefore, we pursued integration of planar
optical imaging with SPECT. We developed and tested
a low-cost prototype system consisting of an add-on
planar bioluminescence/fluorescence optical module
for a dedicated small animal SPECT device (U-SPECT-
II, MILabs B.V., Utrecht, the Netherlands) [21-24].
Methods
Optical module for small animal SPECT
The prototype optical imaging (OI) module was fitted
onto the U-SPECT-II [21,22] installed at the LUMC
(Leiden, the Netherlands) as is shown in Figure 1. The
optical module consists of three main components: 1) a
light tight ‘dark box’ ⑤, 2) a very sensitive CCD camera
③, and 3) a bright light source ⑥. Details about these
components will be given in later paragraphs. The dark
box was designed in such a way that when the module is
in ‘open’ position, the handling of the animals in the bed
of the U-SPECT is not hampered. When the module is
‘closed’, the CCD camera on top of the box is shielded
from ambient light and can produce a total-body top-
view bioluminescent image of the animal via a mirror
⑪. For photographic and fluorescence imaging, the ani-
mal is illuminated by the light source via two optic fibers
④ entering the box and small mirrors ⑩ reflecting the
light onto the bed ①. Excitation and emission light fil-
ters, well adapted to the spectral profile of the fluores-
cent dye under study, can be added to the system.
For SPECT scans, the animal bed is moved by an XYZ
stage into the U-SPECT ⑨ collimator. For the OI pos-
ition, the bed is held in the same position as used for
placing an animal in the bed (U-SPECT ‘bed eject pos-
ition’). Alternatively, by mounting the OI module on a
separate ‘docking station’, it can also be used as an inde-
pendent optical imaging device. The docking station al-
lows for parallel use of the SPECT and OI module.
Dark box
The dark box uses a rail system to slide over the table,
enabling animal placement. The sliding mechanism con-
sists of a U-profile mounted on the box and rails ⑧
mounted on the table that contains the XYZ stage to
move the bed mounted at the front side of the U-
SPECT. When the box slides to its closed position, it is
lowered by about 1 cm. In this way, the U profiles lock
over the rails. Blackboard paint has been applied on the
rails and the U-profile to ensure the light tightness in
locked position.
To further block ambient light, all joints on the box
have been sealed with Sikaflex-221 (Sika AG, Baar, Zug,
Switzerland) sealant. Blackboard paint is applied to the
inside of the box to avoid light reflections. A black ABS-
plastic insert ⑦ has been fitted to cover the entrance of
the U-SPECT to prevent leakage of ambient light into
the dark box and to avoid reflections from the metallic
SPECT entrance. This insert was made with a tight fit to
the entrance of the existing scanner, leaving maximum
space to handle the animals on the bed. With the insert
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to select the region of interest (ROI) in the U-SPECT ac-
quisition software [21,22]. Remaining light leaks mea-
sured inside the closed black box were closed using tape
sealants.
Camera, lens, and mirror
To allow for the detection of weak bioluminescence and
fluorescence signals, an Andor iKon-M 912BV scientific
CCD camera (Andor Technology plc., Belfast, UK) with a
very low dark current level was used for recording OI im-
ages. This camera is based on a CCD77-00 (e2v Technolo-
gies Ltd., Essex, UK) with 512×512 pixels (24×24 μm)
and has a quantum efficiency between ~50% and ~95% in
the wavelength region of 400-900 nm. With the 16-bit
camera read-out at a rate of 50 kHz, the read noise was
below 2 counts/pixel. By means of an air-cooled Peltier
element, the CCD operating temperature was set to −65°C,
reducing the dark current to ~0.006 elec/pix/s. The camera
was fully controlled by the accompanying Andor Solis
software.
The CCD camera was equipped with a Fujinon (Fujifilm
Corp., Tokyo, Japan) CF25HA-1 lens ⑬. This lens has a
fixed focal length (F) of 25 mm. To collect as much of the
emitted luminescence as possible, we selected a lens
whose diaphragm could be set as large as F/1.4. An emis-
sion filter holder ⑫ (50 mm diameter) was mounted in
front of the lens. A lens hood was integrated with the
filter holder to avoid stray light entering the lens/filter
combination.
A mirror was placed above the animal bed (Figure 1) to
direct the emitted light to the CCD camera and generate a
top-view image of an entire mouse. The selected Edmund
Optics enhanced aluminum mirror (Edmund Optics Inc.,
Barrington, NJ, USA) has a high reflective index in the
wavelength region of interest: between ~85% and ~98%
for wavelengths larger than 450 nm.
Fluorescence excitation light
To excite fluorescent dyes, an illumination setup was
constructed to expose the whole animal (bed in OI pos-
ition) with a relatively high intensity of (excitation) light
at the appropriate wavelength.
An MI-150 fiber optic illuminator (Edmund Optics
Inc., Barrington, NJ, USA) with a 150-W EKE halogen
light bulb produced a high intensity bundle of light (450
to 800 nm), covering our wavelength range of interest
for fluorescence imaging. Light from the illuminator was
guided to an excitation filter box ② using a 0.25 inch
glass fiber bundle guide. In the filter box, the spectrum
of the excitation light can be tailored to a particular dye
using a 12.5-mm diameter filter. After the filter, the light
was split into two fiber bundles that enter the dark box
next to the camera. The light from the fibers was reflected
by two small mirrors above the bed to illuminate the
mouse from two directions. Light leakage at the fiber
bundle entrance points was prevented by applying cable
glands.
Imaging with U-SPECT-BioFluo
With the U-SPECT-BioFluo device bioluminescence, fluor-
escence, and SPECT scans of a mouse can be made in a
sequential fashion. The SPECT measurement settings are
setup as described earlier for the U-SPECT [21,22]. To per-
form the optical measurements, the OI module is closed
and the animal bed is moved to the OI position. After
Figure 1 Overview of the U-SPECT-BioFluo platform. (1) Animal bed. (2) Excitation filter box. (3) Camera. (4) Optical fiber bundle. (5) Dark
box. (6) Light source. (7) Black ABS-plastic insert. (8) U-profile light lock. (9) U-SPECT. (10) Mirrors for excitation light. (11) Mirror directing light
from the bed to the camera. (12) Lens hood and emission filter holder. (13) Camera lens.
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and/or fluorescent images can be recorded by the CCD
camera and stored with the Solis software for further off-
line analysis with Matlab (MathWorks Inc., Natick, MA,
USA).
Grayscale photograph
Grayscale images are recorded by the CCD camera to
provide an anatomical context for the bioluminescence,
fluorescence, and SPECT images. The grayscale images
are recorded under white light illumination without the
use of emission and excitation filters. To avoid satur-
ation of the CCD image for our minimal exposure time
(50 ms), the lens diaphragm is set to F/22 and the iris of
the light source is set to a minimum. The F/22 dia-
phragm allows for sharp photographs of the animal in
OI position.
Bioluminescence imaging
The bioluminescence images are recorded without the
use of excitation light and an emission filter. To provide
total darkness in the module, the fiber optic illuminator
is switched off and a light stop is put in the excitation
filter box to block light entering the module via leaks in
the illuminator. To collect a maximum of biolumines-
cent photons in a reasonable exposure time (<90 s), the
largest possible lens diaphragm (F/1.4) is used.
Fluorescence imaging
During fluorescence imaging, the object or animal is
continuously illuminated using an appropriate excitation
filter for the dye under study. With a specific emission
filter in front of the CCD camera lens, only the emitted
fluorescent signal is recorded by the camera.
The CCD exposure time was kept to a minimum by
using the largest possible lens diaphragm (F/1.4) and
fully opening the iris of the illuminator. During imaging,
the exposure time was adjusted to obtain images in
which the brightest fluorescence spots have pixel values
larger than half the full pixel ADC range.
Illumination calibration
The measured images are corrected for the non-uniform
illumination pattern at the mouse bed by making calibra-
tion measurements. This is done by making an image
(without emission filter) of the illumination pattern using
a flat sheet of white paper in the OI position. The corre-
sponding iris, diaphragm, and excitation filter are used for
the grayscale or fluorescence calibration. The exposure
time has to be adjusted to avoid CCD saturation. Since the
bioluminescent images do not require illumination, they
do not require such a calibration.
Image processing
The optical images from the CCD camera are processed
offline with Matlab. Both the fluorescence and photo-
graphic calibration images are blurred with a Gaussian
filter of 7.30 mm full width at half maximum (FWHM)
to suppress small scale non-uniformities of the calibra-
tion paper sheet itself. The resulting calibration images
are subsequently normalized by scaling their maximum
pixel value to 1. The photographic and fluorescent im-
ages are corrected for the non-uniform illumination by
dividing them by the corresponding normalized calibra-
tion image.
3D SPECT images are reconstructed from the SPECT
list-mode data with MILabs reconstruction software ver-
sion 2.38. Proper energy and background windows are
set and data is reconstructed to an isotropic voxel grid
of 0.2 mm using a pixel-based ordered subset expect-
ation maximization (POSEM) algorithm [25] which in-
cludes compensation for distance-depending blurring
[26]. No attenuation correction is applied. For compari-
son to the optical images, a (2D) SPECT sum image is
made by summing the voxel values along the vertical
direction. For anatomical reference, the biolumines-
cence, fluorescence, and SPECT sum images are shown
in color on top of the grayscale photographic image for
pixel values above an adjustable threshold. For biolumin-
escence and fluorescence, this is straightforward as the
same CCD camera is used to record these images. Over-
lay of the SPECT sum image was done by matching the
mouse contours to the grayscale images of the mouse.
Performance characterization
To evaluate the multimodal imaging capabilities of the U-
SPECT-BioFluo setup, pilot experiments were performed
using a phantom and tumor-bearing mice injected with a
multimodal tracer. Optical images were also acquired and
processed on an IVIS Spectrum with Living Image soft-
ware (Caliper Life Sciences Inc., Hopkinton, MA, USA).
Bioluminescence imaging on the IVIS was done with open
filter settings.
The fluorescent dye CyAL-5.5b (λex,max =674 nm;
λem,max =693 nm) [27] was used for the phantom and the
multimodal tracer. For the fluorescence measurements on
the IVIS, the (built-in) 640-nm excitation and 680-nm
emission filters were selected. Their bandwidths were re-
spectively 30 nm and 20 nm. However, for the OI module
we selected a commercial filter (Edmund Optics TechSpec
Fluorescence Bandpass, Barrington, NJ, USA) with a cen-
ter wavelength of 692 nm and wider bandwidth of ~40 nm
to match the dye’s emission peak and to detect a larger
part of the emission spectrum. From the same filter series
another filter with ~40 nm bandwidth was used to excite
this dye. To minimize the spectral overlap of the excitation
and emission filters, an excitation center wavelength of
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the filter was largely overlapping the dye’s absorption
spectrum. Both commercial filters have a 93% transmis-
sion within their passbands and a blocking factor >10
6
for wavelengths outside their passbands. This blocking
factor is lower for non-perpendicular incident light. So,
some excitation light reflected by the object and inci-
dent on the emission filter might still pass that filter
causing the so-called excitation light leakage back-
ground in fluorescence images,
Phantom measurements
A phantom was generated, via a slightly modified pro-
cedure as described by Pleijhuis et al. [28], to evaluate
the attenuation and resolution for the fluorescence and
SPECT signals as function of tissue depth. This phantom
(Figure 2) consisted of a cylinder of tissue simulating gel,
in which a capillary, uniformly filled with a fluorescence/
SPECT compound, was inserted under an oblique angle.
The gel consisted of a 1% (w/w) agarose solution that was
prepared by dissolving agarose (Roche, Basel, Switzerland)
in 50 mL water under continuous heating and stirring.
After cooling down to 40°C, 170 μM hemoglobin from bo-
vine blood (Sigma Aldrich, St. Louis, MO, USA) was added
to the solution to obtain an optically tissue equivalent gel
[28]. The solution was poured into a 50-mL tube (Falcon,
BD Biosciences, San Jose, CA, USA). After further cooling
and solidification, the tube was removed and the gel was
given blunt ends using a scalpel.
A 200-μMC y A L - 5 . 5 b solution was mixed 3:1 with a
99mTc-eluate (~1.3 GBq/mL). A glass capillary (inner
diameter 0.9 mm) containing 50 μL of this mixture and
closed by epoxy glue [29] was inserted into the gel. Prior
to inserting the capillary in the phantom, we used the blue
coloration to visually confirm that the fluorescent dye
(CyAL-5.5b) was uniformly distributed in the capillary.
The phantom was placed in the U-SPECT-BioFluo bed,
and a grayscale and a fluorescence image were recorded.
Subsequently, a 20-min SPECT scan was made with the
ROI containing the entire phantom. At last, fluorescence
measurements were made on the IVIS for control.
In vivo measurements
Mouse scans were performed to interpret the different
bioluminescent, fluorescent, and SPECT images for a
practical preclinical case series of four animals. Tumor
lesions were generated in Balb/c nude mice (6 to 8
weeks of age) by transplanting 4 T1-luc +tumor cells
(0.25 ·10
5) ,w i t hf i r e f l yl u c i f e r a s eg e n ee x p r e s s i o n ,i n t o
the fourth mammary fatpad [30].
For fluorescence and SPECT imaging, the previously
reported multimodal tracer
111In-MSAP-RGD [30], con-
taining the above mentioned CyAL-5.5b dye, was used.
Twenty-four hours prior to imaging, the mice were
injected intravenously with this tracer (40 μg, 18 nmol,
10 MBq).
For bioluminescence imaging, the mice were injected
intraperitoneally with 150 mg/kg D-Luciferin (Xenogen
Corp., Alameda, CA, USA) in PBS. Ten to twenty minutes
after this injection, the mice were placed in the transpar-
ent U-SPECT-BioFluo bed and first imaged on the IVIS.
Afterwards, the bed with the mouse was immediately
clicked on the stage of the U-SPECT-BioFluo for optical
imaging followed by 30 min of SPECT imaging. The mice
were anesthetized by means of Hypnorm/Dormicum/
water (1:1:2; 5 μL/g i.p.). The protocol timeline is shown
in Figure 3. These animal experiments were performed in
accordance with Dutch welfare regulations and approved
by the ethics committee of the Leiden University Medical
Center under reference 2013/12189.
Results
After installing the optical module on the U-SPECT, the
optical image pixel size for the top-view image of the bed
was found to be 0.36 mm. We verified the light tightness
of the closed dark box by recording an image with a large
lens diaphragm and an exposure time of 60 s, but without
any optical filters or light source. This measurement re-
sulted in a zero mean ambient light background level
(standard deviation: 1.3 counts/pixel).
Phantom measurements
In Figure 4, the fluorescence and SPECT imaging results
of the cylindrical phantom with the thin capillary source
are shown both for the U-SPECT-BioFluo (500 ms expos-
ure time) and the IVIS (1 s exposure time). Optical images
obtained with U-SPECT-BioFluo and with IVIS are very
similar. For SPECT reconstruction from list mode data, a
20% wide energy window has been set around the 140 keV
99mTc photopeak. The background windows for triple win-
dow scatter correction [31] were set to 124 to 136 keV and
166 to 184 keV. POSEM with 16 subsets and 6 iterations
was performed for reconstructing 3D SPECT images. The
Figure 2 Schematic diagram of the tissue simulating gel
phantom. (1) Phantom. (2) Fluorescent and radioactive capillary.
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Gaussian low pass filter (FWHM 0.47 mm).
By adjusting the color scale threshold of the fluores-
cence image, sharp identification of the most superficial
part of the capillary can be exchanged for a slight in-
crease in the in-depth visibility. For the low threshold
image, the threshold has been set at about the background
level of the phantom which is due to e.g. excitation light
leakage through the emission filter, fluorescence emission
light scatter, and autofluorescence of the phantom [32].
In Figure 4A, the SPECT signal is also shown. In the
top-view image, the 3D reconstructed SPECT data are
vertically summed for 1:1 comparison with the fluores-
cence measurement. In the side view, the SPECT data
are summed horizontally. In Figure 5A, the fluorescence
and SPECT signal strength as a function of the capillary
Figure 3 Protocol timeline for in vivo measurements. The injection moments of
111In-MSAP-RGD (CyAL-5.5b dye), D-Luciferin, and subsequent
imaging periods are indicated.
Gel phantom - overlay SPECT No filter No filter
A: U-SPECT-BioFluo
Top-view
Fluorescence,
High threshold
Top-view
Fluorescence, 
Low threshold
Top-view
SPECT sum
Side-view
SPECT sum
B: IVIS
Top-view
Fluorescence, 
High threshold
Top-view
Fluorescence, 
Low threshold
Figure 4 Phantom imaging results. (A) Fluorescence (500 ms exposure time) and SPECT imaging on the U-SPECT-BioFluo. (B) Fluorescence
imaging on the IVIS (1s exposure time).
van Oosterom et al. EJNMMI Research 2014, 4:56 Page 6 of 11
http://www.ejnmmires.com/content/4/1/56depth are shown. Line profiles (~1 mm wide) along the
axial direction of the capillary were made from the top-
view images for both modalities (Figure 5B). The axial
position along these line profiles was converted into the
capillary depth by using the inclination angle of the ca-
pillary determined from the SPECT side-view image
Figure 4A. Both Figures 4A and 5 clearly demonstrate
that while the SPECT signal barely suffers from attenu-
ation in this phantom, the fluorescence signal of the uni-
formly distributed dye (CyAL-5.5b) is decreasing with
depth. The IVIS and our OI module show a similar at-
tenuation behavior; at 7 mm the signal has already
dropped by ~30%, and at 14 mm it is close to the fluor-
escence background level of the phantom. This decrease
can be attributed to the light attenuation and scatter by
hemoglobin and water in the phantom. A similar attenu-
ation is observed in tissue [33].
The resolution curves of the fluorescence and SPECT
signals (Figure 6A,B,C) were obtained by making ~1-mm
wide line profiles in the top-view images orthogonal to the
capillary corresponding to different depths (Figure 6D).
Again, the depths have been obtained from the capillary
inclination angle. For comparison, these curves have been
normalized to their maximum signal. Like the signal
strength, the resolution of the fluorescence images also
shows severe depth dependence. At 6 mm depth, the width
of the fluorescence profile was still close to that of the
SPECT profile, namely ~1.2 mm (FWHM). At 14 mm
depth, the resolution decreased to ~1.7 mm (FWHM) and
the peak value was just 2.5 times the background. Both
widths are largely determined by the 0.9 mm diameter of
the capillary itself. Around 22 mm depth, the fluorescence
signal can no longer be distinguished from the background.
In vivo measurements
Figure 7 presents the imaging results obtained from the
different modalities in both U-SPECT-BioFluo and IVIS.
Figure 7A shows respectively the bioluminescence, fluor-
escence, and SPECTsum images recorded with U-SPECT-
BioFluo. The exposure time for the bioluminescence
measurement was 60 s and for the fluorescence measure-
ment 300 ms, as the fluorescent signal was much stronger.
On the IVIS (Figure 7B), the exposure times were respect-
ively 30 s and 1 s. The IVIS images are similar to those of
the in-house developed OI. The bioluminescence images
clearly show the viable tumor component, where lucifer-
ase converts D-Luciferin in bioluminescent light.
In the U-SPECT-BioFluo bioluminescence images in
Figure 7A, one can notice some hot pixels that may be
caused by absorption of
111In-based gamma radiation in
the CCD chip. This radiation was emitted by the radio-
active component of the multimodal tracer
111In-RGD-
MSAP. A median filter of 4 ×4 pixels has been applied
to remove these hot pixels. For the POSEM reconstruc-
tion (16 subsets and 6 iterations) of the SPECT scan, a
20% wide energy window has been set around the 171
keV
111In photopeak. Background windows of 151 to
167 keV and 205 to 226 keV were chosen for the scatter
correction. A 3D Gaussian filter (FWHM 1.18 mm) has
been applied after reconstruction.
Looking at the figures, it becomes clear that the
signal-depth related effects severely limit the diagnostic
utility of the optical images. Nevertheless, the superfi-
cially located mammary tumors could be depicted using
both optical technologies. Other than in the phantom
setup, here the effect of fluorescence threshold changes
was minimal. However, in the image representing the
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Figure 5 Effects of depth-dependent attenuation. (A) Fluorescence signal (phantom background level subtracted) and SPECT signal of
capillary versus depth in gel phantom. The maximum SPECT and fluorescence signals have been normalized to 1. (B) The positions of the axial
line profiles are indicated in the top-view image of the phantom.
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level that a tiny part of tumor seems to be ‘missing’ with
respect to the optical images. We believe that the inten-
sity of the signal of deeper located cells in SPECT can
cause slightly different locations of the tumor compared
to the tumor as is visualized by optical imaging: Optical
imaging mainly displays the surface of the tracer distri-
bution, while the SPECT shows deeper structures in the
mouse very clear as well which affects also the sum
image. On the other hand, the SPECT images revealed a
substantial uptake of
111In-RGD-MSAP in other regions
of the mouse, e.g. the liver and kidneys, a finding that
correlates with previously reported biodistribution stud-
ies [30]. The difference in detectability between the
different modalities also becomes apparent when one
zooms in on the tumor itself: SPECT images in Figure 7C
show heterogeneity of tracer uptake (e.g. an area with
less accumulated tracer) that can not be seen in fluores-
cence images. Earlier studies confirm that microSPECT
enables to visualize and quantify tracer heterogeneity in
tumors [24,34].
Discussion
The rise of optical techniques for molecular imaging
purposes has resulted in a demand for dedicated modal-
ities. One of today’s challenges lies in placing optical
findings in perspective to nuclear medicine technologies.
There is a trend to combine nuclear medicine with sup-
plementary read-outs provided by other modalities. One
very practical solution is to integrate multiple modalities
on a single platform to prevent deformation issues. For
this reason, we developed an optical module that can be
provided as an add-on to the U-SPECT-II modality for pre-
clinical nuclear medicine. Using luciferase-gene-modified
tumor cells and multimodal tracers that combine radio-
nuclear and optical properties [10-12], we incorporated
bioluminescence and fluorescence imaging in a 3D SPECT
imaging setting.
This initial pilot study underlined that the prototype de-
sign (see Figure 1) provided such a small CCD image
background that both bioluminescence and fluorescence
imaging could be successfully achieved. We used com-
mercially available 40 nm wide bandpass filters specifically
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Figure 6 Comparison of image blurring for SPECT and fluorescence. (A,B,C) SPECT and fluorescence line profiles orthogonal to the capillary
at different depths in the phantom. The maximum signal of each profile has been normalized to 1. (D) The positions of the line profiles are
indicated in the top-view image.
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http://www.ejnmmires.com/content/4/1/56Figure 7 Imaging results for a mouse with a 4 T1-luc+tumor. Bioluminescence images are obtained by D-Luciferin injection. Fluorescence
and SPECT images are obtained by injection of multimodal tracer
111In-RGD-MSAP. (A) U-SPECT-BioFluo. Bioluminescent images both with and
without median filter applied. (B) IVIS. (C) U-SPECT-BioFluo: 1-mm thick horizontal SPECT slices (anterior to posterior). Organs have been indicated
in the SPECT images. White circles indicate the tumor location in the slices.
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http://www.ejnmmires.com/content/4/1/56tailored to the excitation and emission spectra of the
CyAL-5.5b dye with wavelengths only slightly different
from the ones used on the IVIS. This small difference may
explain the difference in the fluorescence attenuation pro-
files shown in Figure 5: Since the absorption coefficient
for hemoglobin is higher at 624 nm than at 640 nm, the
excitation light is somewhat more attenuated in the phan-
tom on our setup than on the IVIS. For future studies with
different dyes other commercial filters can be incorpo-
rated. The current halogen excitation lamp and CCD cam-
era of the prototype already allow for excitation across the
450- to 800-nm spectrum.
Reasoning that accurate evaluation of the pharmaco-
kinetics and distribution of a new (optical) imaging
tracer is of paramount importance for any form of future
clinical translation, we have used the in-depth informa-
tion provided by SPECT to place the optical findings in
perspective. In the present study we illustrate that, using
a phantom setup and a multimodal angiogenesis tracer
(
111In-RGD-MSAP) in an orthotopic mouse mammary
tumor model, the SPECT/bioluminescence/fluorescence
combination proposed in this paper may help prevent
misconceptions of the tracer’s specificity that could
otherwise have resulted from using an optical evaluation
only. The genetically engineered bioluminescent signal
was confined to the tumor spread, while the fluorescent
and radioactive emissions were used to define the distri-
bution of the multimodal tracer used in this study.
While the SPECT images show the complete distribu-
tion profile of the tracer used [30], the fluorescence im-
ages of both our in-house developed OI module as well
as the IVIS images, only detected superficial emissions
originating from the tumor. SPECT images clearly show
tracer uptake e.g. in the liver (see Figure 7). In this case,
possible toxicity issues due to unwanted uptake and re-
tention in organs would have been missed with fluores-
cence imaging.
Where the preclinical SPECT findings are constant
with depth, both the optical detectability and resolution
degrade as functions of depth (see Figures 5 and 6). Fac-
tors contributing to the degradation of optical signals
are signal attenuation and scattering - both increase with
depth and occur for both the excitation light and emit-
ted signal. In the case of fluorescence imaging, ‘leakage’
of excitation light through the filters and autofluores-
cence (depends on the tissue type) may raise the back-
ground signal. Even with NIR fluorescent dyes such as
indocyanine green (ICG), these effects have shown to
limit the use of fluorescence to superficial applications
[32]. This said, the added value of optical imaging in
superficial surgical guidance and/or pathological imaging
situations is obvious and is driving the development of
optical imaging tracers or multimodal tracers that con-
tain an optical component [11,12].
In a future version of the OI module, the filter place-
ment could be automated to enable fast switching between
different fluorescent emissions, e.g. for multispectral im-
aging. This could then be combined directly with multi-
isotope capabilities of SPECT, to allow for simultaneous
evaluation of even multiple multimodal tracers. With UV
transparent and more sensitive optics (e.g. larger aperture
or deeper CCD cooling), it may become possible to detect
much weaker signals such as the Cerenkov luminescence
emitted by PET tracers [32]. As the U-SPECT-II can be
adapted to perform collimated imaging of PET tracers
(VECTor, [35,36]), this might even enable combined Ce-
renkov and PET imaging studies, which may help in the
interpretation of Cerenkov findings. In addition, the used
SPECT can be equipped with CT, further expanding the
integration of imaging to a triple or quadruple imaging
platform [37].
Conclusion
We evaluated a prototype optical add-on module that
integrates optical imaging with a dedicated small animal
SPECT system. This combination allows for complemen-
tary and registered imaging of bioluminescent, fluores-
cent, and SPECT signatures in a single scan session. The
high-resolution and highly quantitative (3D) SPECT in-
formation about tracer kinetics and/or biodistribution
can improve the interpretation of the fluorescence and
bioluminescence images.
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